Safeguard Scientifics is a holding company in wind-down mode, managing and monetizing a portfolio of minority equity stakes in private, venture-stage technology and healthcare companies. Safeguard stopped making new investments in January 2018 and is now focused exclusively on exiting its remaining positions and returning cash to shareholders. Safeguard holds stakes typically ranging from roughly 19% to 42% in its portfolio companies, and influences them through board representation and management support rather than direct operations. Safeguard itself generates no operating revenue — it makes money only when portfolio companies are sold or recapitalized. The value Safeguard ultimately recovers depends on exit valuations, each portfolio company's debt and preferred equity waterfall, and Safeguard's ownership percentage at the time of sale. The remaining portfolio is concentrated in healthcare IT and marketing technology, with five core positions — Moxe Health, Prognos Health, meQuilibrium, Clutch Holdings, and InfoBionic — that management believes are the primary source of expected exit value, estimated at $25M–$45M in aggregate. Several other positions have already been exited for negligible proceeds through lender-led restructurings. Safeguard's only cash outflows are corporate operating expenses, which it expects to reduce to roughly $1.5M/year after delisting from Nasdaq and outsourcing its G&A functions. Excess cash from exits will be returned to shareholders via special dividends, with the monetization process expected to take approximately two years.